Resveratrol as a Pan-HDAC Inhibitor Alters the Acetylation Status of Jistone Proteins in Human-Derived Hepatoblastoma Cells

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Venturelli, Sascha ^a   Berger, Alexander ^a   Böcker, Alexander ^b   Busch, Christian ^c   Weiland, Timo ^a   Noor, Seema ^c   Leischner, Christian ^a   Schleicher, Sabine ^a   Mayer, Mascha ^d   Weiss, Thomas S ^e   Bischoff, Stephan C ^d   Lauer, Ulrich M ^a   Bitzer, Michael ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b EVOTEC AG   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d UNIVERSITY OF HOHENHEIM   (Germany)

^e UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; RESVERATROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL STRAIN HEPG2; CHICKEN; CONCENTRATION (PARAMETERS); EMBRYO; EMBRYOTOXICITY; ENZYME INHIBITION; EX VIVO STUDY; HEPATOBLASTOMA; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOLECULAR MECHANICS; NONHUMAN;

ACETYLATION; ANIMALS; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHICK EMBRYO; COMPUTER SIMULATION; HEPATOBLASTOMA; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HUMANS; LIVER NEOPLASMS; MOLECULAR DOCKING SIMULATION; STILBENES;

EID: 84883340186     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073097     Document Type: Article

References (67)

1. Soleas GJ, Diamandis EP, Goldberg DM, (1997) Resveratrol: a molecule whose time has come? and gone? Clin Biochem 30: 91-113.
2. Leiro J, Arranz JA, Parama A, Alvarez MF, Sanmartin ML, (2004) In vitro effects of the polyphenols resveratrol, mangiferin and (-)-epigallocatechin-3-gallate on the scuticociliate fish pathogen Philasterides dicentrarchi. Dis Aquat Org 59: 171-174.
3. Langcake P, Pryce R, (1976) The production of resveratrol by Vitis vinifera and other members of the Vitaseae as a response to infection or injury. Physiol Plant Pathol 9: 77-86.
4. Creasy L, Coffee M, (1988) Phytoalexin production potential of grape berries. J Am Soc Horti Sci 113: 230-234.
5. Kopp P, (1988) Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the 'French paradox'? Eur J Endocrinol 138: 619-620.
6. Sun AY, Simonyi A, Sun GY, (2002) The "French Paradox" and beyond: neuroprotective effects of polyphenols. Free Radical Biol Med 32: 314-318.
7. Collins MA, Neafsey EJ, Mukamal KJ, Gray MO, Parks DA, et al. (2009) Alcohol in moderation, cardioprotection, and neuroprotection: epidemiological considerations and mechanistic studies. Alcohol Clin Exp Res 33: 206-219.
8. Kawada N, Seki S, Inoue M, Kuroki T, (1998) Effect of antioxidants, resveratrol, quercetin, and N-acetylcysteine, on the functions of cultured rat hepatic stellate cells and Kupffer cells. Hepatology 27: 1265-1274.
9. Wadsworth TL, Koop DR, (1999) Effects of the wine polyphenolics quercetin and resveratrol on pro-inflammatory cytokine expression in RAW 264.7 macrophages. Biochem Pharmacol 57: 941-949.
10. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, et al. (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218-220.
11. ElAttar TM, Virji AS, (1999) Modulating effect of resveratrol and quercetin on oral cancer cell growth and proliferation. Anticancer Drugs 10: 187-193.
12. Shakibaei M, Kuzhuvelil HB, Aggarwal BB, (2003) Resveratrol addiction: To die or not to die. Mol Nutr Food Res 53: 115-128.
13. Haigis MC, Sinclair DA, (2010) Mammalian sirtuins: biological insights and disease relevance. Annu Rev Pathol 5: 253-295.
14. Fulda S, (2010) Resveratrol and derivatives for the prevention and treatment of cancer. Drug Discov Today 15: 757-765.
15. Clement MV, Hirpara JL, Chawdhury SH, Pervaiz S, (1998) Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumour cells. Blood 92: 996-1002.
16. Tinhofer I, Bernhard D, Senfter M, Anether G, Loeffler M, et al. (2001) Resveratrol, a tumor-suppressive compound from grapes, induces apoptosis via a novel mitochondrial pathway controlled by Bcl-2. Faseb J 15: 1613-1615.
17. Billard C, Izard JC, Roman V, Kern C, Mathiot C, et al. (2002) Comparative antiproliferative and apoptotic effects of resveratrol, epsilon-viniferin and vine-shots derived polyphenols (vineatrols) on chronic B lymphocytic leukaemia cells and normal human lymphocytes. Leuk Lymphoma 43: 1991-2002.
18. Mgbonyebi OP, Russo J, Russo IH, (1998) Antiproliferative effect of synthetic resveratrol on human breast epithelial cells. Int J Oncol 12: 865-869.
19. Wolter F, Akoglu B, Clausnitzer A, Stein J, (2001) Downregulation of the cyclin D1/Cdk4 complex occurs during resveratrol-induced cell cycle arrest in colon cancer cell lines. J Nutr 131: 2197-2203.
20. Ding XZ, Adrian TE, (2002) Resveratrol inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Pancreas 25: 71-76.
21. Holian O, Wahid S, Atten MJ, Attar BM, (2002) Inhibition of gastric cancer cell proliferation by resveratrol: role of nitric oxide. Am J Physiol Gastrointest Liver Physiol 282: 809-816.
22. Kampa M, Hatzoglou A, Notas G, Damianaki A, Bakogeorgou E, et al. (2000) Wine antioxidant polyphenols inhibit the proliferation of human prostate cancer cell lines. Nutr Cancer 37: 223-233.
23. Kim YA, Lee WH, Choi TH, Rhee SH, Park KY, et al. (2003) Involvement of p21WAF1/CIP1, pRB, Bax and NFkappaB in induction of growth arrest and apoptosis by resveratrol in human lung carcinoma A549 cells. Int J Oncol 23: 1143-1149.
24. Ahmad N, Adhami VM, Afaq F, Feyes DK, Mukhtar H, (2001) Resveratrol causes WAF-1/p21-mediated G(1)-phase arrest of cell cycle and induction of apoptosis in human epidermoid carcinoma A431 cells. Clin Cancer Res 7: 1466-1473.
25. Kozuki Y, Miura Y, Yagasaki K, (2001) Resveratrol suppresses hepatoma cell invasion independently of its anti-proliferative action. Cancer Lett 167: 151-156.
26. Kuo PL, Chiang LC, Lin CC, (2002) Resveratrol- induced apoptosis is mediated by p53-dependent pathway in HepG2 cells. Life Sci 72: 23-34.
27. Acharya MR, Sparreboom A, Venitz J, Figg WD, (2005) Rational development of histone deacetylase inhibitors as anticancer agents: a review. Mol Pharmacol 68: 917-932.
28. Ellis L, Atadja PW, Johnstone RW, (2009) Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther 8: 1409-1420.
29. Marks PA, Xu WS, (2009) Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem 107: 600-608.
30. Kelly WK, O'Connor OA, Marks PA, (2002) Histone deacetylase inhibitors: from target to clinical trials. Expert Opin Invest Drugs 11: 1695-1713.
31. Esteller M, Herman JG, (2002) Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol 196: 1-7.
32. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, et al. (2007) Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109: 31-39.
33. Campas-Moya C, (2009) Romidepsin for the treatment of cutaneous T-cell lymphoma. Drugs Today 45: 787-795.
34. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, et al. (2003) Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425: 191-196.
35. Dayangaç-Erden D, Bora G, Ayhan P, Kocaefe C, Dalkara S, et al. (2009) Histone deacetylase inhibition activity and molecular docking of (e)-resveratrol: its therapeutic potential in spinal muscular atrophy. Chem Biol Drug Des 73: 355-364.
36. Thasler WE, Weiss TS, Schillhorn K, Stoll PT, Irrgang B, et al. (2003) Charitable State-Controlled Foundation Human Tissue and Cell Research: Ethic and Legal Aspects in the Supply of Surgically Removed Human Tissue For Research in the Academic and Commercial Sector in Germany. Cell Tissue Bank 4: 49-56.
37. Thasler WE, Schlott T, Kalkuhl A, Plän T, Irrgang B, et al. (2006) Human tissue for in vitro research as an alternative to animal experiments: a charitable "honest broker" model to fulfil ethical and legal regulations and to protect research participants. Altern Lab Anim 34: 387-392.
38. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, et al. (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112.
39. Hamburger V, Hamilton HL, (1951) A series of normal stages in the development of the chick embryo. Dev Dyn 195: 231-272.
40. Fechner S, Busch C, Oppitz M, Drews U, Meyer-Wittkopf M, (2008) The chick embryo as a model for intrauterine ultrasound-guided heart intervention. Ultrasound Obstet Gynecol 31: 277-283.
41. Busch C, Drews U, Eisele SR, Garbe C, Oppitz M, (2008) Noggin blocks invasive growth of murine B16-F1 melanoma cells in the optic cup of the chick embryo. Int J Cancer 122: 526-533.
42. Berger A, Venturelli S, Kallnischkies M, Böcker A, Busch C, et al. (2012) Kaempferol, a new nutrition-derived pan-inhibitor of human histone deacetylases. J Nutr Biochem, in press.
43. Abassi YA, Xi B, Zhang W, Ye P, Kirstein SL, et al. (2009) Kinetic cell-based morphological screening: prediction of mechanism of compound action and off-target effects. Chem Biol 16: 712-723.
44. Weiland T, Berger A, Essmann F, Lauer UM, Bitzer M, et al. (2012) Kinetic Tracking of Therapy-Induced Senescence Using the Real-Time Cell Analyzer SP System. ASSAY and Drug Development Technologies 10: 289-295.
45. Lee TK, Lau TC, Ng IO, (2002) Doxorubicin-induced apoptosis and chemosensitivity in hepatoma cell lines. Cancer Chemother Pharmacol 49: 78-86.
46. Venturelli S, Berger A, Weiland T, Zimmermann M, Häcker S, et al. (2011) Dual antitumour effect of 5-azacytidine by inducing a breakdown of resistance-mediating factors and epigenetic modulation. Gut 60: 156-165.
47. Menegola E, Di Renzo F, Broccia ML, Giavini E, (2006) Inhibition of histone deacetylase as a new mechanism of teratogenesis. Birth Defects Research Part C: Embryo Today: Reviews 78: 345-353.
48. Meeran SM, Ahmed A, Tollefsbol TO, (2010) Epigenetic targets of bioactive dietary components for cancer prevention and therapy. Clin Epigenetics 1: 101-116.
49. Ho E, Dashwood RH, (2010) Dietary manipulation of histone structure and function. World Rev Nutr Diet 101: 95-102.
50. Chung S, Yao H, Caito S, Hwang JW, Arunachalam G, et al. (2010) Regulation of SIRT1 in cellular functions: role of polyphenols. Arch Biochem Biophys 501: 79-90.
51. Park LK, Friso S, Choi SW, (2011) Nutritional influences on epigenetics and age-related disease. Proc Nutr Soc 4: 1-9.
52. Dashwood RH, Myzak MC, Ho E, (2006) Dietary HDAC inhibitors: time to rethink weak ligands in cancer chemoprevention? Carcinogenesis 27: 344-349.
53. Boily G, He XH, Pearce B, Jardine K, McBurney MW, (2009) SirT1-null mice develop tumors at normal rates but are poorly protected by resveratrol. Oncogene 28: 2882-2893.
54. Pacholec M, Bleasdale JE, Chrunyk B, Cunningham D, Flynn D, et al. (2010) SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem 285: 8340-8351.
55. Hu Y, Liu J, Wang J, Liu Q, (2011) The controversial links among calorie restriction, SIRT1, and resveratrol. Free Radical Biology and Medicine 51: 250-256.
56. Liu B, Ghosh S, Yang X, Zheng H, Liu X, et al. (2012) Resveratrol rescues SIRT1-dependent adult stem cell decline and alleviates progeroid features in laminopathy-based progeria. Cell Metab 16: 738-750.
57. Spallotta F, Cencioni C, Straino S, Nanni S, Rosati J, et al. (2013) A nitric oxide-dependent cross-talk between class I and III histone deacetylases accelerates skin repair. J Biol Chem 288: 11004-11012.
58. Juan ME, Maijó M, Planas JM, (2010) Quantification of trans-resveratrol and its metabolites in rat plasma and tissues by HPLC. J Pharm Biomed Anal 51: 391-398.
59. Colom H, Alfaras I, Maijó M, Juan ME, Planas JM, (2011) Population pharmacokinetic modeling of trans-resveratrol and its glucuronide and sulfate conjugates after oral and intravenous administration in rats. Pharm Res 28: 1606-16021.
60. Colin D, Lancon A, Delmas D, Lizard G, Abrossinow J, et al. (2008) Antiproliferative activities of resveratrol and related compounds in human hepatocyte derived HepG2 cells are associated with biochemical cell disturbance revealed by fluorescence analyses. Biochimie 90: 1674-1684.
61. Liao PC, Ng LT, Lin LT, Richardson CD, Wang GH, et al. (2010) Resveratrol arrests cell cycle and induces apoptosis in human hepatocellular carcinoma Huh-7 cells. J Med Food 13: 1415-1423.
62. Aldana-Masangkay GI, Sakamoto KM (2011) The role of HDAC6 in cancer. J Biomed Biotechnol DOI: 875824.
63. Armeanu S, Pathil A, Venturelli S, Mascagni P, Weiss TS, et al. (2005) Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357. J Hepatol 42: 210-217.
64. Venturelli S, Armeanu S, Pathil A, Hsieh CJ, Weiss TS, et al. (2007) Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma. Cancer 109: 2132-2141.
65. Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK, (2004) High absorption but very low bioavailability of oral resveratrol in humans. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 32: 1377-1382.
66. Boocock DJ, Faust GE, Patel KR, Schinas AM, Brown VA, et al. (2007) Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 16: 1246-1252.
67. Ndiaye M, Kumar R, Ahmad N, (2011) Resveratrol in cancer management: where are we and where we go from here? Ann N Y Acad Sci 1215: 144-149.